SOAT1 and hepatocellular carcinoma: Altogether, these results suggest that EYA2 acts as a tumor suppressor to prevent hepatocarcinogenesis and the malignant phenotype of HCC through the SOCS3-mediated blockade of JAK/STAT signaling, providing a molecular basis for the observed increased aggressiveness in EYA2 loss tumors (Fig. 7).